Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Intravitreal Injection of Ziv-Aflibercept in the Treatment of Choroidal and Retinal Vascular Diseases Publisher



Hodjatjalali K1 ; Mehravaran S2 ; Faghihi H1 ; Hashemi H1 ; Kazemi P3 ; Rastad H3, 4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Noor Ophthalmology Research Center, Noor Eye Hospital, Tehran, Iran
  2. 2. Department of Ophthalmology, Stein Eye Institute, David Geffen School of Medicine, University of California in Los Angeles, Los Angeles, CA, United States
  3. 3. Noor Research Center for Ophthalmic Epidemiology, Noor Eye Hospital, Tehran, Iran
  4. 4. Department of Epidemiology and Biostatics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Current Ophthalmology Published:2017


Abstract

Purpose To investigate the short-term outcomes after intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases. Methods Thirty-four eyes of 29 patients with age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion (RVO) received a single dose intravitreal injection of 0.05 ml ziv-aflibercept (1.25 mg). Visual acuity, spectral domain optical coherence tomography (SD-OCT) activity, and possible side effects were assessed before and at 1 week and 1 month after the intervention. Results At 1 month after treatment, mean central macular thickness (CMT) significantly decreased from 531.09 μm to 339.5 μm (P < 0.001), and no signs of side effects were observed in any subject. All patients responded to treatment in terms of reduction in CMT. The improvement in visual acuity was statistically non-significant. Conclusion Our findings suggest that a single dose intravitreal injection of ziv-aflibercept may have acceptable relative safety and efficacy in the treatment of patients with intraocular vascular disease. The trial was registered in the Iranian Registry of Clinical Trials (IRCT2015081723651N1). © 2017 Iranian Society of Ophthalmology
Related Docs
1. Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab, Ophthalmic Surgery Lasers and Imaging Retina (2020)
2. Safety and Bioavailability of Complete and Half-Dose Intravitreal Ziv-Aflibercept in an Experimental Model: Contralateral Eye Study, Ophthalmic Surgery Lasers and Imaging Retina (2019)
Experts (# of related papers)
View all Related Experts
Elham Ashrafi (1)
Mohammad Zarei (1)